http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Systemic Lupus Erythematosus를 동반한 Multiple sclerosis
이지현,이기주,윤성호,부귀범,손현화,박유환,정춘해,김진호,정원영 조선대학교 부설 의학연구소 1998 The Medical Journal of Chosun University Vol.23 No.2
Multiple sclerosis and lupus erythematosus are chronic, potentially disabling diseases of unknown cause. It is a rare occasion that the finding of both diseases occurs in one patient. Because both diseases may affect the central nervous system, it may be difficult at times to differentiate symptoms of lupus erythematosus from those of multiple sclerosis. As far as we know, there was no case report of SLE in multilple sclerosis in Korea. We report a case of multiple sclerosis accompanied by SLE.
권희석,이승휘,권순욱,주원남,박은호 漢陽大學校 環境科學硏究所 1991 環境科學論文集 Vol.12 No.-
신도시 계획에 따른 환경파괴 및 변화가 예상되는 분당지구의 어족자원을 보호하기 위하여 신도시 건설이전의 어류분포상을 조사하였다. 분당지구에는 잉어과 8종, 기름종개과 4종, 메기과, 뱀장어과, 송사리과, 드렁허리과, 극락어과, 구굴무치과 및 둑중개과 각 1 종을 포함하여 9 개과 19종이 분포하고 있었다. 최근 환경오염으로 감소추세에 있는 송사리, 드렁허리 및 버들 붕어가 이 지역에 존재한다는 것은 주목할 만한 것으로 특히 늪말지역의 늪지대는 신도시 건설 후에도 현재의 환경을 보존하여 이 지역 초, 중, 고등학교의 어류생태학 교육장으로 활용함이 좋을 것이다. 따라서 이 지역의 각별한 보호와 분별있는 개발이 요망된다. The freshwater fish fauna of Bundang Region, Kyungki-do, Korea, where dramatic environmental changes will be expected due to new city project, was censused to establish base line data for natural conservation program. Nineteen species belonging to 9 families were collected in this region. They were mainly cyprinids and cobitids. The Oryzias latipes, Monopterus albus, and Macropodus chinensis which are rare fish in recent years were found in this region. A swamp region called Neupmal is of particular interest in ichthyology excursion site for primary, middle and high school boy. Therefore, careful organization of new city plan and preservation of ichthyological fauna are strongly recommended.
Lee, Su Jin,Lee, Seon Young,Lee, Weon Sup,Yoo, Jin San,Sun, Jong-Mu,Lee, Jeeyun,Park, Se Hoon,Park, Joon Oh,Ahn, Myung-Ju,Lim, Ho Yeong,Kang, Won Ki,Park, Young Suk Springer US 2017 Investigational new drugs Vol.35 No.6
<P><B>Summary</B></P><P><I>Background</I> Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a first-in-human phase I study of tanibirumab in patients with solid tumors refractory to standard chemotherapy. Primary endpoints were evaluating safety, pharmacokinetics (PKs), estimating maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). <I>Methods</I> We designed our study to escalate tanibirumab at 9 different dose levels with a 3 + 3 method and tanibirumab (1–28 mg/kg) was administered intravenously on D1, 8, 15 in 28-day courses. Dose limiting toxicities (DLTs) were only assessed during the first cycle of treatment and response evaluation was performed every 2 cycles. The effects of tanibirumab on several angiogenic factors were analyzed. <I>Results</I> From October 2011 to September 2013, a total of 26 patients with refractory solid tumors were enrolled. The median age was 58 years (range, 27–75) and 20 patients were male. The most common tumor type was colorectal cancer (<I>N</I> = 19) and seven patients had a history of previous bevacizumab treatment. As hemangioma continued to occur, the final dose level, 28 mg/kg, was not performed. DLTs were not found, and the MTD was confirmed to be 24 mg/kg. Hemangioma was observed in 16 patients (61.5%), but all were grade 1–2 and disappeared after discontinuation of the study drug. Among the 18 patients in the efficacy set, no objective response was observed, but 11 patients showed stable disease. PKs were characterized by dose-dependent linear exposure and the mean trough concentrations exceeded biologically relevant target levels at 12 mg/kg and above. Serum VEGF, soluble VEGFR-2, and PlGF increased at the 4 mg/kg dose level and above. <I>Conclusions</I> Treatment with tanibirumab showed a tolerable toxicity profile and modest clinical efficacy in patients with refractory solid tumors. A phase II trial of tanibirumab is ongoing now.</P><P><B>Electronic supplementary material</B></P><P>The online version of this article (doi:10.1007/s10637-017-0463-y) contains supplementary material, which is available to authorized users.</P>
Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth
( Weon Ju Lee ),( Hyun Bo Sim ),( Yong Hyun Jang ),( Seok Jong Lee ),( Do Won Kim ),( Soon Ho Yim ) 대한피부과학회 2016 Annals of Dermatology Vol.28 No.4
Background: Pattern hair loss is a very common problem. Although effective therapeutics for the treatment of pattern hair loss have been used, novel therapeutic modalities are still required to enhance hair growth. Objective: We investigated the efficacy and safety of a complex (ALAVAX) of 5-aminolevulinic acid (5-ALA) and glycyl-histidyl-lysine (GHK) peptide for the treatment of pattern hair loss. Methods: Forty-five patients with male pattern hair loss were treated with ALAVAX 100 mg/ml (group A), ALAVAX 50 mg/ml (group B) or placebo (group C) once a day for 6 months. Total hair count, hair length, hair thickness, patient’s assessment and adverse events were evaluated at month 1, 3, and 6. Results: An increase in hair count for 6 months was 52.6 (p<0.05) in group A, 71.5 (p<0.05) in group B, and 9.6 in group C. The ratio of changes in hair count between group B (2.38) and group C (1.21) at 6 months showed a statistically significant difference (p<0.05). The proportion above good satisfaction was higher in group A (26.7%) than in the other groups (group B: 14.3%, group C: 7.1%). There was no statistically significant difference in hair length and hair thickness among 3 groups at 6 months. There was no adverse event in 3 groups. Conclusion: Our study showed that a complex of 5-ALA and GHK peptide may be considered as one of the complementary agents for the treatment of male pat-tern hair loss. (Ann Dermatol 28(4) 438∼443, 2016)
( Weon Ju Lee ),( Sang Lim Kim ),( Yoon Seok Choe ),( Yong Hyun Jang ),( Seok Jong Lee ),( Do Won Kim ) 대한피부과학회 2015 Annals of Dermatology Vol.27 No.4
Background: Acne is an inflammatory skin disorder caused by inflammatory biomarkers. Magnesium ascorbyl phosphate (MAP) is a stable precursor of vitamin C. It achieves a constant delivery of vitamin C into the skin and has antioxidative effects. Objective: We performed this study to evaluate the effect of MAP on the expression of inflammatory biomarkers in cultured sebocytes. Methods: Reverse transcription- polymerase chain reaction (RT-PCR) and enzyme- linked immunosorbent assay were performed for inflammatory cytokines and matrix metalloproteinases (MMPs) before and after treatment of cultured sebocytes with MAP (10-2 M), lipopolysaccharide (LPS) (5 μg/ml) and a combination of MAP and LPS. RT-PCR and western blotting were also performed for antimicrobial peptides (AMPs) and Toll-like receptor (TLR)-4 before and after treatment of cultured sebocytes with MAP, LPS, and a combination of MAP and LPS. Quantification of lipid peroxidation was also conducted. Results: The increased expression of inflammatory cytokines after treatment of cultured sebocytes with LPS was decreased after treatment with MAP. MMPs, AMPs, and TLR-4 were decreased after treatment of cultured sebocytes with MAP and a combination of MAP and LPS, and increased after treatment of cultured sebocytes with LPS alone. Lipid peroxidation was significantly decreased after treatment of cultured sebocytes with MAP and a combination of MAP and LPS. MAP decreased the increased lipid peroxidation after treatment of cultured sebocytes with LPS. Conclusion: MAP may be an effective alternative agent to improve inflammatory reactions in acne. (Ann Dermatol 27(4) 376∼382, 2015)